INSPIREMD 1/18 DL-0001 Net Assets
INSPIREMD 1/18 DL-0001 net assets. Based on the latest financial reports, INSPIREMD 1/18 DL-0001 (II2) has net assets worth €55.20 Million EUR (≈ $64.54 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€69.40 Million ≈ $81.14 Million USD) and total liabilities (€14.20 Million ≈ $16.60 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is INSPIREMD 1/18 DL-0001 growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €55.20 Million |
| % of Total Assets | 79.54% |
| Annual Growth Rate | 13.27% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 66.24 |
Net Assets of INSPIREMD 1/18 DL-0001 (2021–2025)
Net assets of INSPIREMD 1/18 DL-0001 from 2021 to 2025. This chart illustrates how INSPIREMD 1/18 DL-0001's net assets have evolved over time, based on quarterly financial data. See how leveraged is INSPIREMD 1/18 DL-0001's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for INSPIREMD 1/18 DL-0001 (2021–2025)
The table below shows the annual net assets of INSPIREMD 1/18 DL-0001 from 2021 to 2025. For live market cap and overall valuation, see II2 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €55.20 Million ≈ $64.54 Million |
+52.97% |
| 2024-12-31 | €36.09 Million ≈ $42.19 Million |
-8.65% |
| 2023-12-31 | €39.50 Million ≈ $46.18 Million |
+127.11% |
| 2022-12-31 | €17.39 Million ≈ $20.33 Million |
-48.13% |
| 2021-12-31 | €33.53 Million ≈ $39.20 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to INSPIREMD 1/18 DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11919800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
INSPIREMD 1/18 DL-0001 Net Assets Breakdown (December 2025)
INSPIREMD 1/18 DL-0001 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €357.49 Million | 647.62% |
| Total Equity | €55.20 Million | 100.00% |
INSPIREMD 1/18 DL-0001 Competitors by Market Cap
The table below lists competitors of INSPIREMD 1/18 DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Puncak Niaga Holdings Bhd
KLSE:6807
|
$19.65 Million |
|
Jindo.Co. Ltd
KO:088790
|
$19.66 Million |
|
Eden Inc Bhd
KLSE:7471
|
$19.67 Million |
|
AJ Advance Technology Public Company Limited
BK:AJA
|
$19.69 Million |
|
Blackrock World Mining Trust Plc
LSE:BRWM
|
$19.62 Million |
|
Delko S.A.
WAR:DEL
|
$19.62 Million |
|
BCWORLD PHARM. Co. Ltd
KQ:200780
|
$19.61 Million |
|
Parkway Corporate Ltd
AU:PWN
|
$19.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INSPIREMD 1/18 DL-0001's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 36,086,000 to 55,201,000, a change of 19,115,000 (53.0%).
- Net loss of 48,786,000 reduced equity.
- New share issuances of 38,714,000 increased equity.
- Other factors increased equity by 29,187,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-48.79 Million | -88.38% |
| Share Issuances | €38.71 Million | +70.13% |
| Other Changes | €29.19 Million | +52.87% |
| Total Change | €- | 52.97% |
Book Value vs Market Value Analysis
This analysis compares INSPIREMD 1/18 DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.27x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.09x to 0.27x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €4.04 | €0.36 | x |
| 2022-12-31 | €2.09 | €0.36 | x |
| 2023-12-31 | €1.81 | €0.36 | x |
| 2024-12-31 | €1.36 | €0.36 | x |
| 2025-12-31 | €1.32 | €0.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently INSPIREMD 1/18 DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -88.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -543.33%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.26x
- Recent ROE (-88.38%) is below the historical average (-75.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -44.49% | -331.88% | 0.11x | 1.18x | €-18.27 Million |
| 2022 | -106.31% | -357.59% | 0.21x | 1.42x | €-20.23 Million |
| 2023 | -50.42% | -320.97% | 0.13x | 1.21x | €-23.87 Million |
| 2024 | -88.69% | -456.63% | 0.15x | 1.30x | €-35.61 Million |
| 2025 | -88.38% | -543.33% | 0.13x | 1.26x | €-54.31 Million |
Industry Comparison
This section compares INSPIREMD 1/18 DL-0001's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $41,410,799,518
- Average return on equity (ROE) among peers: -32.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INSPIREMD 1/18 DL-0001 (II2) | €55.20 Million | -44.49% | 0.26x | $19.63 Million |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $17.76 Billion | 5.42% | 0.47x | $168.20K |
| BIORETEC OY (0TN) | $9.76 Million | -97.14% | 0.20x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $388.36 Billion | 11.79% | 0.37x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $683.20 Million | 13.73% | 0.12x | $711.77 Million |
| HeraMED Limited (1I4) | $2.59 Million | -168.10% | 0.60x | $27.68 Million |
| Medtronic PLC (2M6) | $1.75 Billion | 30.35% | 0.38x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $3.02 Billion | -19.02% | 0.05x | $305.26 Million |
| AVITA Medical Inc (51KB) | $84.74 Million | -31.47% | 0.16x | $172.49 Million |
| BRAINCOOL AB (5YL) | $111.74 Million | -54.84% | 0.19x | $18.88 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.33 Billion | -20.20% | 0.10x | $107.57 Million |
About INSPIREMD 1/18 DL-0001
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard c… Read more